Horizon Kinetics Asset Management LLC Raises Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Horizon Kinetics Asset Management LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,682 shares of the company’s stock after acquiring an additional 443 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in CRISPR Therapeutics were worth $420,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in CRSP. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the period. Baker BROS. Advisors LP grew its stake in shares of CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after acquiring an additional 743,075 shares during the period. State Street Corp grew its stake in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the period. Raymond James Financial Inc. bought a new stake in shares of CRISPR Therapeutics in the fourth quarter worth approximately $3,231,000. Finally, Van ECK Associates Corp grew its position in CRISPR Therapeutics by 5,269.3% during the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after buying an additional 81,464 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CRSP. Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday, February 12th. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their target price for the company from $60.00 to $99.00 in a report on Friday, February 14th. Finally, Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $73.11.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the transaction, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $42.82 on Tuesday. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $75.91. The firm has a fifty day moving average price of $43.06 and a 200 day moving average price of $45.51. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -9.80 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.